Skip to content
10-K

Annual Report

Semnur Pharmaceuticals, Inc. SMNR SMNRW

0001193125-26-082642

← back to feed
Filed
Feb 27, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 25, 2026 230.21M sh
Shares Diluted FY 2025 · Dec 31, 2025 204.78M sh
Shares Diluted FY 2025 · Dec 31, 2024 200M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$5.87M
Operating Cash Flow restated FY 2025 · Dec 31, 2024 −$4.89M
Cash And Equivalents FY 2025 · Dec 31, 2025 $20K
Cash And Equivalents FY 2025 · Dec 31, 2024 $12K
Stockholders Equity FY 2025 · Dec 31, 2025 −$20.75M
Stockholders Equity restated FY 2025 · Dec 31, 2024 −$42.78M
Stockholders Equity restated FY 2025 · Dec 31, 2023 −$38.09M
Current Liabilities FY 2025 · Dec 31, 2025 $10.17M
Current Liabilities restated FY 2025 · Dec 31, 2024 $35K
Total Liabilities FY 2025 · Dec 31, 2025 $22.1M
Total Liabilities restated FY 2025 · Dec 31, 2024 $49.47M
Current Assets FY 2025 · Dec 31, 2025 $596K
Current Assets restated FY 2025 · Dec 31, 2024 $6M
Total Assets FY 2025 · Dec 31, 2025 $1.35M
Total Assets restated FY 2025 · Dec 31, 2024 $6.68M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.78
Eps Diluted FY 2025 · Dec 31, 2024 −$0.02
Eps Basic FY 2025 · Dec 31, 2025 −$0.78
Eps Basic FY 2025 · Dec 31, 2024 −$0.02
Sga Expense FY 2025 · Dec 31, 2025 $157.87M
Sga Expense FY 2025 · Dec 31, 2024 $2.98M
Rd Expense FY 2025 · Dec 31, 2025 $2.55M
Rd Expense FY 2025 · Dec 31, 2024 $1.71M
Net Income FY 2025 · Dec 31, 2025 −$160.42M
Net Income restated FY 2025 · Dec 31, 2024 −$4.69M
Operating Income FY 2025 · Dec 31, 2025 −$160.42M
Operating Income restated FY 2025 · Dec 31, 2024 −$4.69M